Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.58) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. The firm’s revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.45 EPS. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Arrowhead Pharmaceuticals Stock Up 3.1 %
Shares of NASDAQ:ARWR opened at $25.86 on Wednesday. The firm has a fifty day moving average of $26.21 and a two-hundred day moving average of $27.35. Arrowhead Pharmaceuticals has a 12-month low of $20.67 and a 12-month high of $39.83. The firm has a market capitalization of $3.21 billion, a P/E ratio of -6.08 and a beta of 0.94.
Analyst Ratings Changes
Get Our Latest Stock Report on ARWR
Insider Activity at Arrowhead Pharmaceuticals
In related news, insider Tracie Oliver sold 9,394 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the transaction, the insider now directly owns 127,107 shares of the company’s stock, valued at approximately $3,213,264.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.50% of the stock is owned by company insiders.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Read More
- Five stocks we like better than Arrowhead Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Investing in Travel Stocks Benefits
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- What Investors Need to Know to Beat the Market
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.